EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency

Stefan D Anker, Tim Friede, Javed Butler, Khawaja M Talha, Marius Placzek, Monika Diek, Anna Nosko, Adriane Stas, Stefan Kluge, Dominik Jarczak, Geraldine deHeer, Meike Rybczynski und 37 weitere

JAMA · 10.06.2025 · 333 (22) · 1965

DOI: 10.1001/jama.2025.3833 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift JAMA, erschienen am 10.06.2025. Verfasst von Stefan D Anker und 48 weiteren Autor:innen. Beteiligte Einrichtung: Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany. Hauptthemen laut MEDLINE: Ferric Compounds, Heart Failure, Hematinics, Iron Deficiencies. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Uncertainty remains about the efficacy of intravenous iron in patients with heart failure and iron deficiency.

Objective

To assess the efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency. Design, Setting, and Participants This multicenter, randomized clinical trial enrolled 1105 patients with heart failure (defined as having a left ventricular ejection fraction of ≤45%) and iron deficiency (serum ferritin level <100 ng/mL; or if transferrin saturation was <20%, a serum ferritin level between 100 ng/mL and 299 ng/mL) at 70 clinic sites in 6 European countries from March 2017 to November 2023. The median follow-up was 16.6 months (IQR, 7.9-29.9 months).

Intervention

Administration of ferric carboxymaltose (n = 558) initially given at an intravenous dose of up to 2000 mg that was followed by 500 mg every 4 months (unless stopping criteria were met) vs a saline placebo (n = 547). Main Outcomes and Measures The primary end point events were (1) time to cardiovascular death or first heart failure hospitalization, (2) total heart failure hospitalizations, and (3) time to cardiovascular death or first heart failure hospitalization in patients with a transferrin saturation less than 20%. All end point events were measured through follow-up. The end points would be considered statistically significant if they fulfilled at least 1 of the following conditions: (1) P ≤ .05 for all 3 of the end point comparisons, (2) P ≤ .025 for 2 of the end point comparisons, or (3) P ≤ .0167 for any of the 3 end point comparisons (Hochberg procedure).

Results

Of the 1105 participants (mean age, 70 years [SD, 12 years]; 33% were women), cardiovascular death or first heart failure hospitalization (first primary outcome) occurred in 141 in the ferric carboxymaltose group vs 166 in the placebo group (hazard ratio, 0.79 [95% CI, 0.63-0.99]; P = .04). The second primary outcome (total heart failure hospitalizations) occurred 264 times in the ferric carboxymaltose group vs 320 times in the placebo group (rate ratio, 0.80 [95% CI, 0.60-1.06]; P = .12). The third primary outcome (cardiovascular death or first heart failure hospitalization in patients with a transferrin saturation <20%) occurred in 103 patients in the ferric carboxymaltose group vs 128 patients in the placebo group (hazard ratio, 0.79 [95% CI, 0.61-1.02], P = .07). A similar amount of patients had at least 1 serious adverse event in the ferric carboxymaltose group (269; 48.2%) vs in the placebo group (273; 49.9%) ( P = .61). Conclusions and Relevance In patients with heart failure and iron deficiency, ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death in the overall cohort or in patients with a transferrin saturation less than 20%, or reduce the total number of heart failure hospitalizations vs placebo. Trial Registration ClinicalTrials.gov Identifier: NCT03036462

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric CompoundsHeart FailureHematinicsIron DeficienciesAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodFerritinsHospitalizationMaltoseStroke VolumeTransferrinFollow-Up StudiesTreatment OutcomeAged, 80 and overProspective StudiesInfusions, Intravenous

Substanzen

ferric carboxymaltoseFerric CompoundsFerritinsHematinicsMaltoseTransferrin

Autor:innen und Institutionen

  • Deutsches Herzzentrum der Charité, Campus Virchow Klinikum, Berlin, Germany.
  • Institute of Health Centre for Regenerative Therapies, German Centre for Cardiovascular Research, partner site Charité Universitätsmedizin, Berlin, Germany.
  • Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.
  • German Centre for Cardiovascular Research, partner site Lower Saxony, Germany.
  • Department of Medicine, University of Mississippi Medical Center, Jackson.
  • Baylor Scott and White Research Institute, Dallas, Texas.

Zitieren

APA

Anker, S. D., Friede, T., Butler, J., Talha, K. M., Placzek, M., Diek, M., Nosko, A., Stas, A., Kluge, S., Jarczak, D., deHeer, G., Rybczynski, M., Bayés-Genís, A., Böhm, M., Coats, A. J. S., Edelmann, F., Filippatos, G., Hasenfuß, G., Haverkamp, W., …, & Karakas, M. (2025). Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency. JAMA, 333(22), 1965. https://doi.org/10.1001/jama.2025.3833

Vancouver

Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M, et al. Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency. JAMA. 2025;333(22):1965. doi:10.1001/jama.2025.3833

BibTeX
@article{Anker2025,
  author = {Anker, Stefan D and Friede, Tim and Butler, Javed and Talha, Khawaja M and Placzek, Marius and Diek, Monika and Nosko, Anna and Stas, Adriane and Kluge, Stefan and Jarczak, Dominik and deHeer, Geraldine and Rybczynski, Meike and Bayés-Genís, Antoni and Böhm, Michael and Coats, Andrew J S and Edelmann, Frank and Filippatos, Gerasimos and Hasenfuß, Gerd and Haverkamp, Wilhelm and Lainscak, Mitja and Landmesser, Ulf and Macdougall, Iain C and Merkely, Bela and Pieske, Burkert M and Pinto, Fausto J and Rassaf, Tienush and Visser-Rogers, Jennifer K and Rosano, Giuseppe and Volterrani, Maurizio and von Haehling, Stephan and Anker, Markus S and Doehner, Wolfram and Ince, Hüseyin and Koehler, Friedrich and Savarese, Gianluigi and Khan, Muhammad Shahzeb and Rauch-Kröhnert, Ursula and Gori, Tommaso and Trenkwalder, Teresa and Akin, Ibrahim and Paitazoglou, Christina and Kobielusz-Gembala, Iwona and Kuthi, Luca and Frey, Norbert and Licka, Manuela and Kääb, Stefan and Laugwitz, Karl-Ludwig and Ponikowski, Piotr and Karakas, Mahir},
  title = {Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {22},
  pages = {1965},
  doi = {10.1001/jama.2025.3833}
}
Kostenlos starten →